Drug intelligence / Profile preview

ABP-431

Development stage: Preclinical
Lead developer: Jiangsu Atom Bioscience & Pharmaceutical
Modality: Small Molecules

Overview

ABP-431 is a small molecule drug being developed by Atom Bioscience (initially by Hangzhou Atom Therapeutics Co., Ltd.) for the treatment of various cancers, including gastric cancer, intestinal neoplasms, and triple-negative breast cancer. The mechanism of action is currently undefined.

Beyond the preview

Go deeper on ABP-431.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABP-431.

Explore the full profile